Literature DB >> 30270315

Decreased Psoas Muscle Computed Tomography Value Predicts Poor Outcome in Peripheral Artery Disease.

Takayuki Sugai1, Tetsu Watanabe1, Yoichiro Otaki1, Jun Goto1, Ken Watanabe1, Taku Toshima1, Tetsuya Takahashi1, Miyuki Yokoyama1, Harutoshi Tamura1, Satoshi Nishiyama1, Takanori Arimoto1, Hiroki Takahashi1, Tetsuro Shishido1, Masafumi Watanabe1.   

Abstract

BACKGROUND: The prognosis of peripheral artery disease (PAD) and comorbid sarcopenia is poor. Some reports indicate that the computed tomography (CT) value of skeletal muscle, which reflects intramuscular fat deposition as well as skeletal muscle mass, is considered a marker of sarcopenia. However, it remains unclear if skeletal muscle area and CT value are associated with poor outcomes in patients with PAD. Methods and 
Results: Psoas muscle area and CT value were measured by manual trace at the level of the third lumbar vertebral body in 327 consecutive patients with PAD undergoing endovascular therapy (EVT). The endpoint was major adverse cardiovascular and limb events (MACLE). There were 60 MACLE during the follow-up period. Patients with MACLE had lower mean psoas muscle CT value than those without. However, there was no significant difference in total psoas muscle area between patients with and without MACLE. Kaplan-Meier analysis demonstrated that the lowest tertile of psoas muscle CT value was associated with the highest risk of MACLE. Multivariate Cox hazard analysis revealed that psoas muscle CT value was associated with MACLE after adjustment for Fontaine class, previous ischemic heart disease, prevalence of diabetes mellitus, brain natriuretic peptide, and serum albumin.
CONCLUSIONS: Psoas muscle CT value is a feasible predictor of MACLE in patients with PAD.

Entities:  

Keywords:  Computed tomography; Intramuscular fat deposition; Peripheral artery disease; Psoas muscle; Sarcopenia

Mesh:

Year:  2018        PMID: 30270315     DOI: 10.1253/circj.CJ-18-0726

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

1.  Adverse Outcomes after Advanced EVAR in Patients with Sarcopaenia.

Authors:  Abdullah O Alenezi; Elizabeth Tai; Arash Jaberi; Andrew Brown; Sebastian Mafeld; Graham Roche-Nagle
Journal:  Cardiovasc Intervent Radiol       Date:  2021-01-03       Impact factor: 2.740

2.  Clinical Outcome and Diverse Risk Factors for Different Therapeutic Target Locations of Peripheral Artery Disease.

Authors:  Toshiyuki Ko; Michiaki Higashitani; Yukari Uemura; Makoto Utsunomiya; Tetsuo Yamaguchi; Akihiro Matsui; Shunsuke Ozaki; Kazuki Tobita; Takahide Kodama; Hiroyuki Morita; Issei Komuro
Journal:  J Atheroscler Thromb       Date:  2019-11-12       Impact factor: 4.928

3.  Non-invasive Quantification of Fat Deposits in Skeletal Muscle Predicts Cardiovascular Outcome in Kidney Failure.

Authors:  Mehdi Keddar; Thibaut Muylle; Emmanuelle Carrie; Pierre Trefois; Maxime Nachit; Ralph Crott; Claudine Christiaens; Bert Bammens; Michel Jadoul; Eric Goffin; Johann Morelle
Journal:  Front Physiol       Date:  2020-02-25       Impact factor: 4.566

Review 4.  Sarcopenia and peripheral arterial disease: a systematic review.

Authors:  Mégane Pizzimenti; Alain Meyer; Anne-Laure Charles; Margherita Giannini; Nabil Chakfé; Anne Lejay; Bernard Geny
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-07-10       Impact factor: 12.910

5.  Association between the psoas muscle index and hospitalization for pneumonia in patients undergoing hemodialysis.

Authors:  Kosei Yamaguchi; Mineaki Kitamura; Takahiro Takazono; Shuntaro Sato; Kazuko Yamamoto; Satoko Notomi; Kenji Sawase; Takashi Harada; Satoshi Funakoshi; Hiroshi Mukae; Tomoya Nishino
Journal:  BMC Nephrol       Date:  2021-11-27       Impact factor: 2.388

6.  The impact of muscle mass loss and deteriorating physical function on prognosis in patients receiving hemodialysis.

Authors:  Mineaki Kitamura; Takahiro Takazono; Kosei Yamaguchi; Satoko Notomi; Kenji Sawase; Takashi Harada; Satoshi Funakoshi; Hiroshi Mukae; Tomoya Nishino
Journal:  Sci Rep       Date:  2021-11-16       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.